SG11202102059YA - Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof - Google Patents

Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof

Info

Publication number
SG11202102059YA
SG11202102059YA SG11202102059YA SG11202102059YA SG11202102059YA SG 11202102059Y A SG11202102059Y A SG 11202102059YA SG 11202102059Y A SG11202102059Y A SG 11202102059YA SG 11202102059Y A SG11202102059Y A SG 11202102059YA SG 11202102059Y A SG11202102059Y A SG 11202102059YA
Authority
SG
Singapore
Prior art keywords
annulene
oxyphenyl
fluoropropyl
pyrrolidin
dichlorophenyl
Prior art date
Application number
SG11202102059YA
Other languages
English (en)
Inventor
Joël Malpart
Montes José Ruiz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202102059YA publication Critical patent/SG11202102059YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11202102059YA 2018-09-07 2019-09-06 Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof SG11202102059YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306177 2018-09-07
PCT/EP2019/073823 WO2020049150A1 (en) 2018-09-07 2019-09-06 Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof

Publications (1)

Publication Number Publication Date
SG11202102059YA true SG11202102059YA (en) 2021-03-30

Family

ID=63637829

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202102059YA SG11202102059YA (en) 2018-09-07 2019-09-06 Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof
SG11202102057SA SG11202102057SA (en) 2018-09-07 2019-09-06 Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202102057SA SG11202102057SA (en) 2018-09-07 2019-09-06 Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

Country Status (18)

Country Link
US (2) US11713296B2 (es)
EP (2) EP3847157B1 (es)
JP (2) JP7398436B2 (es)
KR (2) KR20210057032A (es)
CN (2) CN112638869A (es)
AR (2) AR116299A1 (es)
AU (2) AU2019335542A1 (es)
BR (2) BR112021003061A2 (es)
CA (2) CA3111359A1 (es)
DK (2) DK3847157T3 (es)
ES (2) ES2923412T3 (es)
HU (2) HUE059527T2 (es)
IL (2) IL281191B (es)
MX (2) MX2021002666A (es)
SG (2) SG11202102059YA (es)
TW (2) TWI803692B (es)
WO (2) WO2020049153A1 (es)
ZA (2) ZA202101006B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN112638869A (zh) * 2018-09-07 2021-04-09 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
KR20220113695A (ko) 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
WO2022001971A1 (zh) 2020-06-28 2022-01-06 南京明德新药研发有限公司 并环吲唑类化合物
KR20230095996A (ko) 2020-10-19 2023-06-29 사노피 치환 6,7-디히드로-5h-벤조[7]아눌렌 화합물 및 이의 유도체, 이의 제조 방법 및 이의 치료적 용도
MX2023004506A (es) 2020-10-19 2023-05-10 Sanofi Sa Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos y sus derivados, procesos para su preparacion y usos terapeuticos de los mismos.
CN118679157A (zh) 2021-12-28 2024-09-20 深圳扬厉医药技术有限公司 四氢环庚吲唑化合物的盐型、晶型
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
WO2023198901A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2023198904A1 (en) * 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023198879A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198903A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n‑propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198905A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015579A1 (en) 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2236056T3 (es) 2001-01-24 2005-07-16 Chiesi Farmaceutici S.P.A. Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
HUP0500573A2 (hu) 2001-08-11 2005-11-28 Bristol-Myers Squibb Pharma Company Trifenil-etilén származékok, mint szelektív ösztrogén receptor modulátorok és ezeket tartalmazó gyógyszerkészítmények
AU2003237084C1 (en) 2002-04-24 2009-03-26 Merck Sharp & Dohme Corp. Estrogen receptor modulators
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
UA85597C2 (ru) 2004-06-25 2009-02-10 Янссен Фармацевтика Н.В. Четвертичные соли как антагонисты ccr2
EP1896391B1 (en) 2005-06-14 2015-08-12 Baylor University Combretastatin analogs with tubulin binding activity
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
WO2009101634A2 (en) 2008-02-13 2009-08-20 Lupin Limited A novel process for the preparation of eszopiclone
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US20120130129A1 (en) 2010-11-16 2012-05-24 Baylor University Efficient Method for Preparing Functionalized Benzosuberenes
JP5886873B2 (ja) 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー N置換アゼチジン誘導体
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2013097773A1 (en) 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
EP3033086B1 (en) 2013-08-14 2021-09-22 Novartis AG Combination therapy for the treatment of cancer
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
KR20160085915A (ko) 2013-12-06 2016-07-18 에프. 호프만-라 로슈 아게 국소 진행성 또는 전이성 에스트로겐 수용체 양성 유방암을 치료하기 위한 에스트로겐 수용체 조절자
CN112457310A (zh) 2014-12-18 2021-03-09 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
IL255148B2 (en) 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
AR107616A1 (es) 2016-02-15 2018-05-16 Sanofi Sa Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
KR102477513B1 (ko) * 2016-11-17 2022-12-16 사노피 신규 치환된 n-(3-플루오로프로필)-피롤리딘 화합물, 그의 제조 방법 및 그의 치료 용도
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN112638869A (zh) 2018-09-07 2021-04-09 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
SG11202104923YA (en) 2018-11-16 2021-06-29 Arqule Inc Pharmaceutical combination for treatment of cancer
BR112021022216A2 (pt) 2019-05-09 2021-12-28 Sanofi Sa Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
CA3159749A1 (en) * 2019-11-04 2021-05-14 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
KR20220113695A (ko) * 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태

Also Published As

Publication number Publication date
CN112638869A (zh) 2021-04-09
JP7398436B2 (ja) 2023-12-14
TW202026280A (zh) 2020-07-16
TW202024032A (zh) 2020-07-01
KR20210057031A (ko) 2021-05-20
KR20210057032A (ko) 2021-05-20
CA3111466A1 (en) 2020-03-12
US20210188772A1 (en) 2021-06-24
JP2021536471A (ja) 2021-12-27
DK3847157T3 (da) 2022-08-08
JP2021536468A (ja) 2021-12-27
US20210188771A1 (en) 2021-06-24
HUE059362T2 (hu) 2022-11-28
MX2021002665A (es) 2021-07-16
AR116300A1 (es) 2021-04-21
CN112638870A (zh) 2021-04-09
ZA202101006B (en) 2022-08-31
WO2020049153A1 (en) 2020-03-12
EP3847157A1 (en) 2021-07-14
ES2923412T3 (es) 2022-09-27
EP3847156A1 (en) 2021-07-14
WO2020049150A1 (en) 2020-03-12
IL281196A (en) 2021-04-29
SG11202102057SA (en) 2021-03-30
US11713296B2 (en) 2023-08-01
AU2019336532A1 (en) 2021-04-01
HUE059527T2 (hu) 2022-11-28
CA3111359A1 (en) 2020-03-12
DK3847156T3 (da) 2022-07-25
EP3847157B1 (en) 2022-05-18
BR112021003061A2 (pt) 2021-05-11
ZA202101079B (en) 2022-09-28
IL281196B (en) 2022-10-01
BR112021003440A2 (pt) 2021-05-18
IL281191B (en) 2022-07-01
JP7413363B2 (ja) 2024-01-15
ES2924738T3 (es) 2022-10-10
IL281196B2 (en) 2023-02-01
IL281191A (en) 2021-04-29
MX2021002666A (es) 2021-07-16
AU2019335542A1 (en) 2021-04-01
TWI803692B (zh) 2023-06-01
EP3847156B1 (en) 2022-05-04
AR116299A1 (es) 2021-04-21

Similar Documents

Publication Publication Date Title
IL281191A (en) Salts of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[7 ]anolene-2-carboxylate and processes for their preparation
IL272166A (en) A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment
IL259609B (en) Method for producing 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(4,2,1-triazol-1-yl)propan-2-ol
NO20054452D0 (no) Fremgangsmate for fremstilling av 5-[(R)-2-(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist
IL268690A (en) (4)- 1-(1-(S-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(1-methyl-H1-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridine-2 (H1)-Onat salts and their crystalline structures and pharmaceutical preparations containing them
LT1981872T (lt) Bifenil-2-ilkarbamo rūgšties 1-[2-(2-chlor-4-{[(r)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrochinolin-5-il)etilamino]metil]}-5-metoksifenilkarbamoil)etil]piperidin-4-ilo esterio gintaro rūgšties druska ir jos naudojimas plaučių susirgimų gydymui
PL1902029T5 (pl) Krystaliczne postacie 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-metoksy-7-[3(-4-metylo-1-piperazynylo)propoksy]-3-chinolino-karbonitrylu i sposoby ich wytwarzania
EP3735243A4 (en) ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
IL287805A (en) 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene -2-carboxylic for use in metastatic or advanced breast cancer patients
EA201401027A1 (ru) НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ ГЕМИНАПАДИЗИЛАТА 5-(2-{[6-(2,2-ДИФТОР-2-ФЕНИЛЭТОКСИ)ГЕКСИЛ]АМИНО}-1-(R)-ГИДРОКСИЭТИЛ)-8-ГИДРОКСИХИНОЛИН-2(1H)-ОНА В КАЧЕСТВЕ АГОНИСТОВ βАДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
IL209815A0 (en) Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
EP3302466A4 (en) 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases
LT3408260T (lt) Kristalinė (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi-izoksazol-5-karboksamido)-2-metilpentanoinė rūgštis ir jos panaudojimai
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
IL266099B (en) N-((3s,4r)-1-((8-chloroquinoxalin-6-yl)carbonyl-3-(4-flurophenyl)piperidin-4-yl)-1-methyl-5-((trifluoromethyl)-1h-pyrazol-3-carboxamide-and therapeutic use thereof
EP4293015A4 (en) BENZIMIDAZOLE COMPOUND OR SALT THEREOF, MANUFACTURE PROCESS AND USE THEREOF, AND INSECTICIDE AND ACARICIDE AND USE THEREOF
MA56071A (fr) Procédés de préparation de 3-bromo-1-(3-chloropyridine-2-yl)-1h-pyrazole-5-carboxylate d'éthyle
EP3927689A4 (en) PROCESSES FOR THE PREPARATION OF (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDINE-3-AMINE OR A SALT THEREOF AND PROCESSES FOR THE PREPARATION OF TOFACITINIB THEREFORE